SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > Ingredients

News in brief

Baxter produces H1N1 vaccine

06-Aug-2009

Baxter has said its Vero cell production technology has made it possible to complete production of its first commercial batches of H1N1 vaccine 12 weeks after receiving the virus strain.

The company believes the speed of this turnaround represents an innovation in vaccine production and is a validation of its proprietary technology.

Baxter is now in discussing distribution plans with health authorities and is also ensuring that the company is in accordance with requirements needed to support marketing approval.

Clinical trials to evaluate the safety of the mock-up vaccine in adults, the elderly and children will begin this month.

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE

Key Industry Events

 

Access all events listing

Our events, Events from partners...